PAREXEL International
United States
About PAREXEL International
515 articles with PAREXEL International
-
Parexel Opens Clinical Trial Supplies and Logistics Depot in Suzhou, China
9/27/2022
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the opening of a new clinical trial supplies and logistics depot in Suzhou, China.
-
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
9/14/2022
Parexel, a leading global clinical research organization, announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
-
Parexel Expands Network of Global Regulatory Experts
9/8/2022
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the appointment of five former regulators to its Regulatory & Access Consulting team, further accelerating the advancement of new treatments for patients worldwide.
-
Addex Therapeutics announced it is canceling its Phase IIb/III study evaluating its drug dipraglurant due to patient recruiting, staffing and pandemic-related issues.
-
Parexel Bolsters Regulatory and Access Offering with Key Appointment
1/11/2022
Parexel announced the appointment of Wyatt Gotbetter as the company’s Head of Worldwide Access Consulting to lead all facets of this growing business with a focus on helping customers position products for market success.
-
EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel
11/15/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the completion of its acquisition by EQT IX fund and funds managed by the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.
-
Parexel Strengthens Clinical Data and Digital Services Offering with Key Appointment
10/4/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the appointment of Stephen Pyke as the company’s Executive Vice President, Clinical Data and Digital Services.
-
Parexel’s Peyton Howell and Sofia Baig Named to 2021 PharmaVOICE 100
8/2/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced that two of its visionary leaders have been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
-
Upon completion of the merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
-
EQT Private Equity and Goldman Sachs Asset Management to acquire Parexel, a leading global clinical research organization, for USD 8.5 billion
7/2/2021
The EQT IX fund and the Private Equity business within Goldman Sachs Asset Management have agreed to acquire Parexel, a leading global clinical research organization from Pamplona Capital Management for an enterprise value of USD 8.5 billion.
-
Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management
7/2/2021
Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund and the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.
-
Parexel Recognized as Most Favored Provider in ISR CRO Phase I Quality Benchmarking Report
5/13/2021
Recognition marks fourth consecutive year as top-ranked Phase I provider to work with; Company ranked among top-two global CROs for Service Provider Leadership, Familiarity, Use and Preference in Phase I
-
Parexel Completes Separation of Parexel Informatics and Medical Imaging Business
1/11/2021
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, announced it has completed the separation of its Parexel Informatics and Medical Imaging business.
-
Parexel Completes Purchase of Roam Analytics’ Natural Language Processing
9/22/2020
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced it has completed the purchase of the Natural Language Processing (NLP) technology assets and transfer of key personnel of Roam Analytics, Inc., a healthcare software company based in San Francisco, California. This strategic move will further stren
-
Parexel’s Deb Tatton Named to 2020 PharmaVOICE 10024-year Parexel veteran recognized as one of the 100 most inspiring people in life sciences for leadership of Parexel’s Global Clinical Operations
8/3/2020
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through Commercialization, announced that Deb Tatton, Senior Vice President, Global Clinical Operations, has been named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry.
-
Parexel Expands Global Regulatory Capabilities with Experts from FDA, EMA, NMPA and Spanish AEMPS
7/23/2020
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, announced the addition of former regulators with significant expertise in oncology, immunotherapy and rare disease to its Regulatory & Access Consulting team, further supporting the advancement of new treatments for patients worldwide.
-
Parexel Adds APANDEMIC and Datavant to Lead Ongoing Advancement of #KeepingPatientsFirst Platform
6/16/2020
New Partners join strategic collaboration, contributing additional technology and life sciences expertise to further accelerate patient access to new COVID-19 treatments
-
Parexel Recognized for High-Quality Service in CRO and Investigative Site Survey Benchmark Reports
4/16/2020
Company earns top marks from both sponsors and investigative sites for service; continues to support customers with innovative and remote approaches during unprecedented time
-
Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Modeling Firm Model Answers
2/20/2020
Company’s expertise and proven approach will enhance the operational scale and global footprint of Parexel’s Clinical Pharmacology, Modeling and Simulation offering to drive more informed and efficient drug development
-
Parexel Unveils Combined Regulatory & Access Consulting Organization to Help Customers Optimize Delivery of New Therapies to Patients
1/9/2020
Integration of world-class Regulatory and Market Access teams will help companies address Clinical, Regulatory and Market Access strategies in parallel to achieve faster, smarter and patient-led development strategy